Biomolecules-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-09-16 ms5000001050298954

我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊

39 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-03-21 Jacinth 来自广东省

想咨询一下这本杂志一般pending review几天？

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-11-08 ms6000000755861927 来自福建省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：11月1日投，11月8号大修

34 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-04-03 柠檬cherry

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：分子相关
经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好

73 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-02-16 ms2000002077912665 来自北京

偏重的研究方向：肿瘤;综述;心血管
经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-11-04 ms3000000019971711 来自上海

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：脑
经验分享：投MDPI

21 0

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-05-04 ms2000000795035219 来自广东省

生信加细胞功能验证好不好投这个刊？

35 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-08-24 120ee8a4m29(暂无昵称) 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：胶质瘤
经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。

31 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-03-01 ms9000000723499418 来自山东省

偏重的研究方向：分子机制
经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收

33 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120915, encodeId=3ba221209153f, content=想咨询一下这本杂志一般pending review几天？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230305/6dde92a22fc046ce97bac5aa409b06eb/2b385598b8c1466f9d564e5a3679cd61.jpg, createdBy=c9cf2486248, createdName=Jacinth, createdTime=Tue Mar 21 22:58:18 CST 2023, time=2023-03-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114935, encodeId=ab61211493588, content=偏重的研究方向：肿瘤;综述;心血管 经验分享：已经投稿一个月了目前还在Under review，作者是大陆医院的还得提供机构邮箱和所有作者CV, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Thu Feb 16 16:43:53 CST 2023, time=2023-02-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166687, encodeId=7d39216668e36, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：投MDPI, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 19:22:40 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154428, encodeId=bf902154428ce, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胶质瘤 经验分享：这是投过的效率最快的杂志，没有之一，7月底投稿，十五天一审，一个大修，一个小修，两个审稿人20+意见，要求十天内完成，不敢怠慢，一周修回，3天后通过，给1天时间校稿，校稿完成当天就出版了，速度简直了，整个投稿周期不到1个月，主编邮件回复非常及时，一天可以来回回复好几次。不过前期准备工作要做好，因为是从cancer letters转过来的，手稿其实已经准备的非常充分了，这个是能快速出版的一个原因。其次，要用官网提供的模板来写，后期校稿就快很多。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48622217394, createdName=120ee8a4m29(暂无昵称), createdTime=Thu Aug 24 21:25:05 CST 2023, time=2023-08-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1211201, encodeId=89ed12112017c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022.3.22 submit，pending review 3.23分配编辑，under review 4.1 major revision 4.8修回 4.11小修 4.12修回接受 4.14online 真的是神速！感谢它让我能毕业了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b886468889, createdName=ms3000001197219082, createdTime=Thu Apr 14 18:01:16 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-04-14 ms3000001197219082

审稿速度:1.0 | 投稿命中率:75.0
经验分享：2022.3.22 submit，pending review
3.23分配编辑，under review
4.1 major revision
4.8修回
4.11小修
4.12修回接受
4.14online
真的是神速！感谢它让我能毕业了！

90 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务